Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
LOXO-292 is an inhibitor of the receptor tyrosine kinase RET.1 It inhibits the phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM). LOXO-292 selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold. It improves survival in a CCDC6-RET gene fusion-positive orthotopic patient-derived xenograft (PDX) mouse model of brain cancer when administered at a dose of 30 mg/kg. Formulations containing LOXO-292 have been used in the treatment of RET mutation- or gene fusion-positive lung or thyroid cancers.
WARNING This product is not for human or veterinary use.
1. Selective RET kinase inhibition for patients with RET-